Mutant of alpha-glucosidase and application thereof
Through site-directed mutation of marine Aspergillus affinis α-glucosidase, mutants I226A/P229S and I226A/P229S/F662S with improved activity were designed, which solved the problem of low activity in the generation of high polymerization IMOs and achieved high efficiency. The widening of the catalytic and substrate spectrum significantly improved the yield and quality of IMOs.
Patent Information
- Application Number
- CN202411419557.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-12
- Publication Date
- 2024-11-15
AI Technical Summary
The existing α-glucosidases have low activity and narrow substrate spectrum in the generation of high polymerization isomaltose (IMOs), which limits the industrial application of biological enzyme methods.
By performing site-directed mutation of marine Aspergillus affinis α-glucosidase, expanding its substrate pocket and broadening the substrate spectrum, the mutants I226A/P229S and I226A/P229S/F662S were designed to enhance their catalytic activity to generate high polymerization IMOs .
The relative enzyme activity of the mutant increased to 170% to 212% of the wild type, significantly broadening the substrate spectrum of the enzyme and successfully catalyzed the production of isomalt hexaose, improving the yield and quality of IMOs.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of gene engineering and enzyme engineering, and specifically relates to a mutant of alpha-glucosidase and application thereof. Background Art
[0002] Isomaltooligosaccharides (IMOs) are oligosaccharide mixtures with a degree of polymerization between 2 and 10 formed by connecting glucose units with α-1,6 bonds. The main components are isomaltose, isomaltotriose and panose. IMOs can promote gastrointestinal motility, improve constipation and promote lipid metabolism. They play an important role in maintaining the balance of intestinal flora and can also be developed as functional foods with broad prospects.
[0003] IMOs are a kind of prebiotics that can effectively promote the growth and reproduction of intestinal probiotics (bifidobacteria), and are called "bifidobacterium growth promoting factors". IMOs with different degrees of polymerization have different effects on the metabolism of intestinal flora. The higher the degree of polymerization, the more significant the impact on the human body. As people pay more and more attention to dietary health, long-chain IMOs (DP≥6) are more resistant to hydrolysis by digestive enzymes and are slowly metabolized by the human body, thereby being retained in the colon for a long time and promoting intestinal absorption. They have important application value and unique nutritional and physiological functions, and considerable economic benefits.
[0004] At present, long-chain IMOs (DP≥6) are mainly produced by hydrolysis of polysaccharides (β-cyclodextrin, glucan, etc.), which has poor specificity, is prone to produce a variety of by-products, and has serious waste of raw materials, high production costs, and difficulty in separating and purifying products. α-Glucosidase can synthesize IMOs using maltose as raw material through transglycosidation, and is a potential candidate enzyme for industrial production. However, most α-glucosidases currently have problems such as narrow substrate spectrum and low activity and cannot produce a large number of high-polymerization IMOs (DP≥6), which greatly limits the industrial application of using bioenzymatic methods to produce IMOs. Site-directed mutagenesis can quickly and efficiently improve the properties of the target protein and is a common method of enzyme engineering. Semi-rational design of the α-glucosidase structure and combined with site-directed mutagenesis technology to develop α-glucosidases with high catalytic activity and the ability to synthesize high-polymerization IMOs (DP≥6) are of great significance to the production of IMOs. Summary of the invention
[0005] In view of the deficiencies of the prior art, one of the purposes of the present invention is to provide a mutant of α-glucosidase by genetic engineering and protein engineering, which has high yield of IMOs and can continuously polymerize until isomaltohexaose is synthesized. The second purpose of the present invention is to provide a recombinant vector or host bacteria expressing the above-mentioned α-glucosidase mutant. The third purpose of the present invention is to provide the application of the above-mentioned α-glucosidase mutant.
[0006] 1. Amino acid residues are represented by the three-letter abbreviations or single-letter symbols using the generally accepted IUPAC nomenclature. DNA nucleic acid sequences are represented by the generally accepted IUPAC nomenclature.
[0007] 2. Mutant identification: "Amino acid replaced by the original amino acid position" is used to indicate the mutated amino acid in the α-glucosidase mutant. For example, I226A means that the amino acid at position 226 is replaced by alanine Ala from the isoleucine Ile of the parent α-glucosidase, and the position corresponds to the amino acid sequence position of α-glucosidase. For example, I226A / P229C means that both the amino acids at positions 226 and 229 are mutated.
[0008] The technical solution of the present invention is summarized as follows: Through site-directed mutagenesis, the substrate pocket of α-glucosidase is enlarged, the substrate spectrum is broadened, and the activity is enhanced to generate high-polymerization IMOs. Aspergillus affinis The α-glucosidase (GenBank: XP_052949979.1) was subjected to amino acid mutation by semi-rational design and site-directed mutagenesis technology, and the amino acid at the corresponding position in the wild-type α-glucosidase sequence was mutated to obtain the α-glucosidase mutant as follows: The mutant I226A / P229S obtained by replacing the isoleucine at position 226 with alanine and the proline at position 229 with serine is shown in SEQ ID NO: 1; or the mutant I226A / P229C / F662S obtained by replacing the phenylalanine at position 226 with aspartic acid, the isoleucine at position 229 with alanine and the phenylalanine at position 662 with serine is shown in SEQ ID NO: 2, which is as follows: SEQ ID NO:1 MVHFTALLASAWLFPVAYGASHSLASSTTPLRSQFTIPASADVGAQLIANVDDPQAVNAQSVCPGYKAFNVKHTGDGFSADLELAGKPNAYGTDVGSLSLTVEYQAKDRLNIQIVPSHVDSSNASWYHLSEDTVPRPKVSPNASIPQSDLFVSWSNEPSFNFKVIRKATGEALFDTEGSVLVYEDQFIEFVTSLPEDYNLYGLGERMSQLRLLKNANLTMYAADIADPIDSNIYGQHPFYLDTRY YKANEQYGPHSRARTSEIDPSQEYVSYSHGVFFRNAHGQEVLLRSEKLIWRTLGGSIDLTFYAGPTQADVTKQYQISTVGLMAPQQYNTLGFHQCRWGYNNWTEFEEVVANFEKFEIPLEYVWADIDYMHGYRNFDNDKHRFSYEDGEKFLSKLHDGGRRWVPIVDAALYIPNPENASDAYETYTRGDADDVFLKNPDGSLYIGAVWPGYTVYPDWHHPKAVEFWANELLVWWKKLAYDGVWYDMA EVSSFCVGSCGTGNLTLNPAHPPFSLPGEPGNVVFDYPEGFNITNATEAASAGASSQAAAGGSGSSPTKTSYLRTTPTAGVRDVDHPPYVINHVQTEHDLAVHAVSPNATHADGVEEYDVHSLYGHQGLNATYQGLLKVWSEKRPFIIGRSTFAGSGKWAGHWGGDNFSKWGSMYFSISQALSFSLFGIPMFGVDTCGFNGNSAELCNRWMQLSAFPFYRNHNVLSAIPQEPYRWASVIDASKAAMKIRYSILPYFYTLFHLAHTTGSTVMRALAWEFPHDPSLAAIDTQFLVGPSVMVVPVLEPHVDSVKGVFPGVGHGEVWYDWYTQRAVDAQPGVNTTIPAPLGHIPVFIRGGSVLPMQEPALTTRDARQTPWSLLASLGTKGTASGQLYLDDGESIHPADTLSVDFVATRSLRASARGTWTEKNALANVTVLGVQEKPGDVSFNGEKIAAESVRYNANSKALHVGGLQKLTAKGAWSRDWVLEW SEQ ID NO:2 MVHFTALLASAWLFPVAYGASHSLASTTPLRSQFTIPASADVGAQLIANVDDPQAVNAQSVCPGYKAFNVKHTGDGFSADLELAGKPNAYGTDVGSLSLTVEYQAKDRLNIQIVPSHVDSSNASWYHLSEDTVPRPKVSPNASIPQSDLFVSWSNEPSFNFKVIRKATGEALFDTEGSVLVYEDQFIEFVTSLPEDYNLYGLGERMSQLRLLKNANLTMYAADAADSIDSNIYGQHPYLDTRY YKANEQYGPHSRARTSEIDPSQEYVSYSHGVFFRNAHGQEVLLRSEKLIWRTLGGSIDLTFYAGPTQADVTKQYQISTVGLMAPQQYNTLGFHQCRWGYNNWTEFEEVVANFEKFEIPLEYVWADIDYMHGYRNFDNDKHRFSYEDGEKFLSKLHDGGRRWVPIVDAALYIPNPENASDAYETYTRGDADDVFLKNPDGSLYIGAVWPGYTVYPDWHHPKAVEFWANELLVWWKKLAYDGVWYDMA EVSSFCVGSCGTGNLTLNPAHPPFSLPGEPGNVVFDYPEGFNITNATEAASAGASSQAAAGGSGSSPTKTSYLRTTPTAGVRDVDHPPYVINHVQTEHDLAVHAVSPNATHADGVEEYDVHSLYGHQGLNATYQGLLKVWSEKRPFIIGRSTFAGSGKWAGHWGGDNSSKWGSMYFSISQALSFSLFGIPMFGVDTCGFNGNSAELCNRWMQLSAFPFYRNHNVLSAIPQEPYRWASVIDASKAAMKIRYSILPYFYTLFHLAHTTGSTVMRALAWEFPHDPSLAAIDTQFLVGPSVMVVPVLEPHVDSVKGVFPGVGHGEVWYDWYTQRAVDAQPGVNTTIPAPLGHIPVFIRGGSVLPMQEPALTTRDARQTPWSLLASLGTKGTASGQLYLDDGESIHPADTLSVDFVATRSLRASARGTWTEKNALANVTVLGVQEKPGDVSFNGEKIAAESVRYNANSKALHVGGLQKLTAKGAWSRDWVLEW The present invention further discloses a recombinant vector or host bacteria for expressing the α-glucosidase mutant. In one embodiment of the present invention, the expression vector for expressing the α-glucosidase and its mutant is pET-22b; the microbial host transformed by the recombinant expression vector is E. coli BL21(DE3).
[0009] The expression vector may also be pMA5 or pPIC9k; the host bacteria may also be Bacillus subtilis or Pichia pastoris.
[0010] The use of the recombinant vector or host bacteria in expressing α-glucosidase mutants and the use of the recombinant vector or host bacteria in preparing IMOs. Using AaGlu-pET-22b as a template, design site-directed mutagenesis primers I226A-F / R, P229S-F / R, F662S-F / R, perform site-directed mutagenesis PCR amplification reaction, and circularize and connect after demethylation to construct a mutant expression vector. The expression vector in this experiment is Pet-22b, and its vector can also be pMA5 or pPIC9k. The successfully constructed mutant expression vector is introduced into Escherichia coli, and the host bacteria can also be Bacillus subtilis or Pichia pastoris. The positive single clones after verification are selected for culture and induced expression, and finally IMOs are successfully synthesized using maltose as a substrate. (See Example 1) The α-glucosidase mutant can be used to cut the α-1,4 bonds between maltose molecules, form α-1,6 bonds through transglycosylation, and then use glucose as an acceptor to synthesize isomaltose, panose, isomaltotriose, isomaltotetraose, and isomaltopentose, and finally continuously polymerize to generate long-chain isomaltohexaose.
[0011] The α-glucosidase mutant can be used to catalyze maltose to produce IMOs. The cells in Example 1 were collected, and the cells were resuspended and broken with Lysis Buffer (20 mM Tirs-HCl, 20 mM imidazole, 500 mM NaCl, pH = 7.4). After centrifugation, the supernatant was purified by nickel column (Ni-NTA) affinity chromatography to obtain a pure enzyme solution of the α-glucosidase mutant. 5mM maltose and 20 μM enzyme solution were added and dissolved in 1 mL 20 mM Tirs-HCl (pH = 5.5), reacted at 55 ° C for 15min, boiled for 10 min to terminate the reaction, and IMOs were detected in the sample. Under the above conditions, the enzyme activity was determined according to the amount of 1 μM maltose consumed per minute. The relative enzyme activity of I226A / P229S was 170% of the wild type, and the relative enzyme activity of F226A / E229W / S662 was 212% of the wild type. (See Example 4) The application of the α-glucosidase mutant in the preparation of IMOs. The experimental results show that the pure enzyme solution of mutant I226A / P229S and mutant I226A / P229S / F662S catalyzes a mixture of 500 g / L maltose and Tris-HCl buffer (0.05 M, pH 5.5) at 55°C for 25 hours. After testing, the substrate conversion rates of the two mutants were improved, which were 1.2 and 1.6 times that of the wild type, respectively, and isomaltohexaose was detected in the product, accounting for 3.5% and 6.8% of the product, respectively. (See Example 5) The experimental steps for obtaining the α-glucosidase mutant of the present invention are summarized as follows: 1. Carrying the ocean Aspergillus affinis The plasmid AaGlu-pET-22b encoding the α-glucosidase gene (AaGlu) was used as a template, and the key amino acid residues of AaGlu were modified by site-directed mutagenesis technology to obtain the target mutant; 2. The site-directed mutagenesis PCR product was Dpn I digestion, self-cyclization, the ligation product was transferred to E. coli BL21(DE3) was used to construct a mutant library, antibiotic screening and induced expression were performed on the positive clones obtained by culture, and mutants with higher activity were screened by converting maltose; 3. The mutant strains with improved activity were sequenced to identify the AaGlu gene, and the sequencing results were compared with the wild type to obtain two AaGlu mutants with improved activity, I226A / P229S and I226A / P229S / F662S; 4. Purify and determine the catalytic activity of the mutant; 5. Use the mutant to catalyze maltose to produce IMOs.
[0012] The invention obtains a mutant I226A / P229S or I226A / P229S / F662S of alpha-glucosidase by site-directed mutagenesis, wherein the relative enzyme activity of the mutant I226A / P229S is 170% of that of the wild type, and the relative enzyme activity of the mutant I226A / P229S / F662S is 212% of that of the wild type, thereby improving the catalytic activity of the enzyme. The mutant I226A / P229S catalyzes 500 g / L maltose to produce IMOs, and the 25 h maltose conversion rate can reach 46.02%, of which isomaltohexaose accounts for 3.5% of the product IMOs. The mutant I226A / P229S / F662S catalyzes 25 h maltose conversion rate can reach 61.32%, of which isomaltohexaose accounts for 6.8% of the product IMOs, while the wild-type AaGlu catalyzes 25 h maltose conversion rate of 38.33%, without the generation of isomaltohexaose, which shows that these two mutants broaden the substrate spectrum of the enzyme. The α-glucosidase mutant of the present invention improves the enzyme activity and realizes the synthesis of isomaltohexaose (see Example 5), which provides a reference for the subsequent production of long-chain IMOs. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 :HPLC identification diagram of IMOs and maltose; Figure 2 : Relative activity graph of AaGlu mutants; Figure 3 :Conversion rate diagram of maltose to IMOs catalyzed by AaGLu mutant; Figure 4 : Distribution diagram of isomaltohexaose production by the AaGLu mutant. DETAILED DESCRIPTION
[0014] The method of the present invention is described below by specific embodiments. Unless otherwise specified, the technical means used in the present invention are methods known to those skilled in the art. In addition, the embodiments should be understood as illustrative rather than limiting the scope of the present invention, and the essence and scope of the present invention are limited only by the claims. For those skilled in the art, various changes or modifications to the material composition and dosage in these embodiments, without departing from the essence and scope of the present invention, also belong to the protection scope of the present invention. The raw materials used in the present invention are all commercially available. Example
[0015] (1) Carrying ocean Aspergillus affinis The AaGlupET-22b plasmid (synthesized by Beijing Qingke Biotechnology Co., Ltd.) encoding the α-glucosidase gene AaGlu was used as a template.
[0016] (2) The mutant primers are as follows: Primer (5'-3') I226A-F: GATCAGCTGACCCAATCGACAGCAATATTTACGGTCAG, Primer (5'-3') I226A-R: AGCTGCATCGGCGGCGTACATCG, Primer (5'-3') P229S-F: GACAGCATCGACAGCAATATTTACGGTCAGCATCCGT, Primer (5'-3') P229S-R GATGCTGTCAGCTGCATCGGCGGC, Primer (5'- 3') F662S-F AACAGCTCCAAATGGGGCAGCATGTATTTTTCCATCT, Primer (5'-3') F662S-R GGAGCTGTTATCGCCGCCCCAGTG, Add each reagent to a 0.2 mL EP tube in the following order: Components Add volume <![CDATA[ddH 2 The]]> 8.5 μL Template (50 ng / μL) 0.5 μL 40 mM dNTP mix 1.25 μL KOD buffer 1.25 μL Upstream primer (125 ng / μL) 0.35 μL Downstream primer (125 ng / μL) 0.35 μL KOD-plus 0.25 μL PCR reaction conditions:
[0017] For demethylation, add 0.35 μL of Dpn I The reaction was carried out at 37 °C for 1 h, and the demethylated product was verified by agarose gel electrophoresis. The gene length was about 3000 bp, and the verification was successful and entered the next step of the experiment.
[0018] For the self-circularization of the PCR product, add the following reagents to a 0.2 mL EP tube: Transformation: Add all ligation products to E. coli In BL21 competent cells, gently mix and place on ice for 30 minutes; heat shock at 42°C for 90 seconds, and immediately place on ice for 5 minutes; add 600 μL LB recovery solution, and culture at 37°C, 220 r / min for 40-60 minutes; centrifuge at 4,000 r / min for 5 minutes, suspend the precipitate with 200 μL LB medium, mix and spread on the resistant plate containing Amp, and after the bacterial solution is fully absorbed, invert and culture at 37°C for 12-16 hours until a single colony appears; pick a single colony for activity detection.
[0019] HPLC detection conditions are: Chromatograph: Agilent 1260; Detector: Evaporative light scattering detector (Alltech Chrom, ELSD6000) Injection: Agilent autosampler; injection volume 10 μL; Column: Alltech Prevail TM Carbohydraye ES (5 μm, 4.6×250 mm, Grace, America); column temperature 30 ℃; Mobile phase: 70% acetonitrile in water; flow rate: 1.2 mL / min.
[0020] The detection peaks of samples and standards are as follows Figure 1 shown.
[0021] Protein purification: Resuspend the cells in Lysis Buffer (20 mM Tirs-HCl, 20 mM imidazole, 500 mM NaCl, pH = 7.4), mix well, add 200 μL lysozyme and 120 μL PMSF, mix well, pour into a beaker and place on ice for 20 min. The cell suspension was disrupted by ultrasound for 15 min (ultrasound 2.5 s, interval 3.0 s). The broken liquid was placed at 4 ℃, 12,000 r / min for 30 min, and the supernatant obtained by centrifugation was combined with Ni-NTA superflow equilibrated with Lysis Buffer for 1 h. The combined liquid was passed through the purification column, and the impurities were eluted with Wash Buffer (20 mM Tirs-HCl, 20 mM imidazole, 500 mM NaCl, pH = 7.4). Then, the target protein was eluted with Elution Buffer (20 mM Tirs-HCl, 500 mM imidazole, 500 mM NaCl, pH = 7.4), and then the Elution Buffer was dialyzed against 20 mM Tirs-HCl (pH = 7.4, containing 150 mM NaCl), and the pure enzyme solution was obtained by ultrafiltration concentration. The protein concentration was determined using Nanodrop 2000. The activity of AaGlu was determined by referring to the following catalytic reaction system: 5 mM maltose and 20 μM enzyme solution were dissolved in 1 mL 20 mM Tirs-HCl (pH=5.5), reacted at 55°C for 15 min, and boiled for 10 min to terminate the reaction. After centrifugation, the supernatant was diluted to an appropriate concentration, filtered through a 0.22 μm water filter membrane into a chromatographic injection bottle, and the product was quantitatively analyzed using the detection method of Example 2.
[0022] The enzyme activity of the present invention is defined as follows: Under standard reaction conditions, 1 mL of 20 mM Tirs-HCl (pH = 5.5), 5 mM maltose and 20 μM pure enzyme solution are uniformly mixed. The reaction mixture is incubated at 55 ° C for 15 min and boiled for 10 min to terminate the reaction. One unit (U) of enzyme is defined as the amount of 1 μM maltose consumed per minute under the above conditions. The relative enzyme activity of the mutant is based on the wild-type enzyme activity as 100%. The relative enzyme activity of the purified mutant and the wild-type was determined by referring to the enzyme reaction system of Example 3. The results are as follows: Figure 2 As shown, the relative enzyme activity of I226A / P229S is 170% of that of the wild type, and the relative enzyme activity of F226A / E229W / S662 is 212% of that of the wild type. The above mutants have improved catalytic activity to maltose.
[0023] The wild-type AaGlu and its mutants purified above were used to catalyze maltose to produce IMOs at 55°C, and the IMOs were determined and identified according to the method of Example 2.
[0024] Through the determination, it was found that the mutants I226A / P229S and F226A / E229W / S662 have high application value and prospects.
[0025] In a 1 L Erlenmeyer flask, add Tris-HCl buffer (0.05 M, pH 5.5) containing 500 g / L maltose and 20 mM AaGlu pure enzyme solution, react at 55 °C, take samples at intervals, and terminate the reaction by boiling for 10 min. Finally, the content of IMOs in the sample was detected by HPLC. The conversion rate of AaGlu mutant and its wild type to produce IMOs from maltose at different reaction times is shown in Figure 2. Figure 3 As shown in the figure, after 25 h of reaction, the maltose conversion rate catalyzed by WT AaGlu can reach 38.33%, the maltose conversion rate of mutant I226A / P229S can reach 46.02%, which is 1.2 times that of the wild type, of which isomaltohexaose accounts for 3.5% of the product IMOs, and the substrate conversion rate of mutant I226A / P229S / F662S can reach 61.32%, which is 1.6 times that of the wild type, of which isomaltohexaose accounts for 6.8% of the product IMOs. The distribution diagram of isomaltohexaose generated from maltose of different mutants is shown in the figure. Figure 4 shown.
[0026] AaGlu Total isomaltooligosaccharide (%) Isomaltose hexaose (%) WT 38.33 0 I226A / P229S 46.02 3.5 I226A / P229S / F662S 61.32 6.8 Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Any person skilled in the art may make various changes or modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.
Claims
1. An α-glucosidase mutant, Features The amino acid sequence of the mutant is based on the amino acid sequence of marine Aspergillus affinis α-glucosidase, wherein the isoleucine at position 226 is replaced by alanine and the proline at position 229 is replaced by serine, as shown in SEQ ID NO:1; or the isoleucine at position 226 is replaced by alanine, the proline at position 229 is replaced by serine, and the phenylalanine at position 662 is replaced by serine, as shown in SEQ ID NO:
2.
2. The α-glucosidase mutant according to claim 1, Features The two mutants were used to catalyze the production of IMOs from maltose, and the enzyme activities were 170% and 212% of the wild type, respectively.
3. The use of the α-glucosidase mutant of claim 1 in forming isomaltohexaose with a high degree of polymerization; the use refers to: the α-glucosidase mutant continuously polymerizes glucose monomers to form α-1,6 bonds, and finally generates.
4. A recombinant vector or host bacteria comprising the coding gene of the α-glucosidase mutant according to claim 1; the expression vector of the α-glucosidase and its mutant is pET-22b; the microbial host used for transformation of the recombinant expression vector is E. coli BL21(DE3).
5. Use of a recombinant vector or host bacteria of the gene encoding the α-glucosidase mutant according to claim 4 in expressing the α-glucosidase mutant.
6. Use of a recombinant vector or host bacteria of the gene encoding the α-glucosidase mutant according to claim 4 in preparing IMOs.
7. A method for preparing a mutant α-glucosidase, Features Cultivate the host bacteria according to claim 4, and collect α-glucosidase from the culture.
8. Use of the α-glucosidase mutant according to claim 1 in preparing IMOs.
